Skip to main content
Fig. 4 | Breast Cancer Research

Fig. 4

From: Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers

Fig. 4

ERX-11 enhances palbociclib ability to reduce proliferation in patient-derived tumor explants. Schematic representation of patient-derived explant (PDE) model is shown (a). Six PDEs (b) were treated with vehicle, ERX-11, palbociclib, or in combination for 72 h. Effect of ERX-11, palbociclib, or combination therapy on Ki-67 expression in ER+ tumors is shown (c, d)

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us